http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
EyePoint Pharmaceuticals (EYPT) Appoints Jay S. Duker, M.D. as Chief Operating Officer
-
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer
-
EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021
-
EyePoint Pharmaceuticals (EYPT) Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ CALM Registry Study at ASRS 39th Annual Meeting
-
EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
-
EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
-
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
-
EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
-
EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
-
EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board
-
EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021
-
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®
-
EyePoint Pharmaceuticals (EYPT) Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD
-
EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD
-
EyePoint Pharmaceuticals (EYPT) Announces New Category III CPT Code for DEXYCU Intraocular Suspension, Approved by the American Medical Association
-
EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association
-
EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index
-
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
-
EyePoint Pharmaceuticals (EYPT) Reports Complete Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901
-
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD
-
EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments
-
EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021
-
EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments
-
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
-
EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
-
EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
-
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
-
EyePoint Pharmaceuticals (EYPT) Provides Business Update and Preliminary Q4 and FY 2020 Net Product Revenues
-
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
-
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
-
EyePoint Pharmaceuticals (EYPT) Announces $16.5 Million Monetization of ILUVIEN Royalty with SWK Holdings Corporation
-
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
-
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
-
EyePoint Pharmaceuticals (EYPT) Announces 1-for-10 Reverse Stock Split
-
EyePoint (EYPT) Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
-
EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
-
EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
-
EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
-
EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
-
EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments
-
EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information
-
EyePoint Pharmaceuticals (EYPT) Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
-
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
-
EyePoint Pharmaceuticals (EYPT) Announces Preliminary Net Product Revenue for Q3
-
EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020
-
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
-
EyePoint Pharmaceuticals (EYPT) Announces New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU
-
EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
-
EyePoint Pharmaceuticals (EYPT) Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
-
EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
